| 2024-11-18 | +1.99 % |
|
| 2024-11-15 | +1.43 % |
|
| 2024-11-13 | -4.76 % |
|
| 2024-11-08 | +1.55 % |
|
| 2024-11-07 | +1.18 % |
|
| 2024-11-05 | +0.87 % |
|
| 2024-11-01 | +0.75 % |
|
| 2024-10-31 | -0.23 % |
|
| 2024-10-29 | -0.98 % |
|
| 2024-10-28 | -3.61 % |
|
| 2024-10-24 | +0.7 % |
|
| 2024-10-17 | +0.52 % |
|
| 2024-10-16 | -0.35 % |
|
| 2024-10-15 | -0.64 % |
|
| 2024-10-14 | +0.08 % |
|
| 2024-10-11 | +1.08 % |
|
| 2024-10-10 | +0.38 % |
|
| 2024-10-09 | +0.42 % |
- ResMed Inc. (RMD) stock increased by 0.42% following a recent transaction where CEO Michael J. Farrell sold shares, which may have contributed to investor confidence alongside positive growth in earnings and quarterly dividends, coupled with optimistic analyst price targets.
- ResMed Inc. (NYSE:RMD) stock rose by 0.42% after the CFO sold 1,000 shares at $233.47 each, indicating strong investor confidence in the company's performance and prospects, as evidenced by its recent earnings beat and dividend increase.
- ResMed Inc. (NYSE:RMD) experienced a 0.42% increase in its stock price, potentially influenced by the CEO's sale of shares, which may indicate confidence in the company's financial standing.
- ResMed Inc. (NYSE:RMD) saw a 0.42% increase in stock price following the CEO's sale of shares, which did not significantly impact his overall holdings, and the company continued to receive positive analyst sentiments and price target upgrades, contributing to investor confidence.
|
| 2024-10-07 | -0.72 % |
|
| 2024-10-04 | -1.87 % |
|
| 2024-10-03 | -0.18 % |
|
| 2024-10-02 | +0.05 % |
|
| 2024-10-01 | -2.2 % |
|
| 2024-09-30 | +2.14 % |
|
| 2024-09-26 | +0.75 % |
|
| 2024-09-24 | +0.39 % |
|
| 2024-09-20 | +0.81 % |
|
| 2024-09-19 | +2.08 % |
|
| 2024-09-18 | -5.12 % |
|
| 2024-09-13 | -0.71 % |
|
| 2024-09-11 | +0.02 % |
|
| 2024-09-10 | +1.32 % |
|
| 2024-08-14 | +0.88 % |
|
| 2024-08-13 | +2.62 % |
|
| 2024-08-12 | -0.9 % |
|
| 2024-08-09 | +1.12 % |
|
| 2024-08-08 | +1.54 % |
|
| 2024-08-07 | -3.61 % |
|
| 2024-08-06 | +1.46 % |
|
| 2024-08-05 | -3.56 % |
|
| 2024-08-02 | +4.23 % |
|
| 2024-08-01 | +0.61 % |
|
| 2024-07-31 | +2.5 % |
|
| 2024-07-25 | +1.04 % |
|
| 2024-07-19 | -0.36 % |
|
| 2024-07-17 | -0.41 % |
|
| 2024-07-16 | +0.73 % |
|
| 2024-07-12 | +2.53 % |
|
| 2024-07-10 | +1.05 % |
|
| 2024-07-05 | +2.82 % |
|
| 2024-07-03 | +0.03 % |
|
| 2024-07-02 | +1.29 % |
|
| 2024-06-27 | +2.71 % |
|
| 2024-06-25 | +0.9 % |
|
| 2024-06-24 | -11.48 % |
|
| 2024-06-21 | -3.49 % |
|
| 2024-06-18 | +0.91 % |
|
| 2024-06-17 | -0.65 % |
|
| 2024-06-11 | -0.7 % |
- The article discusses the recent sale of ResMed Inc. (NYSE:RMD) CEO Michael J. Farrell's shares, which amounted to approximately $3.1 million, and the subsequent decrease in his direct holdings of ResMed stock. The stock went down -0.7% last night following these transactions, potentially due to investors monitoring insider selling activities, although insider transactions under Rule 10b5-1 plans are usually prearranged and may not fully reflect insider sentiment, especially when the company is performing well and reports robust financial performance.
- The article discusses Seven Eight Capital LP's reduction in ResMed Inc. (RMD) shares by 92.9% in the 4th quarter, leading to a 0.7% decrease in RMD stock. The decline in the stock could potentially be attributed to institutional investors selling off their shares, including Azimuth Capital Investment Management LLC, Exencial Wealth Advisors LLC, and others, impacting the overall stock price negatively.
|
| 2024-06-10 | +0.36 % |
|
| 2024-06-07 | -0.31 % |
- The article discusses how CIBC Asset Management Inc reduced its position in ResMed Inc. (NYSE:RMD) by 8.6% in the fourth quarter, which could have contributed to the -0.31% decrease in ResMed stock. Additionally, other hedge funds and institutional investors also made changes to their positions in the company, and insider selling activity was noted. With such adjustments and sales within the company, along with market factors, it is likely that these actions influenced the decrease in ResMed stock.
- The article discusses how ResMed (RMD) has seen a ROCE increase to 21%, outpacing the industry average, with growing returns on capital employed and an increase in capital employed over the last five years, indicating potential for further growth; the stock went down -0.31% last night, which could be due to general market fluctuations or profit-taking by investors despite the positive trends in the company.
- The article reports that KBC Group NV reduced its holdings in ResMed Inc. (NYSE:RMD) by 88.1% during the fourth quarter, leading to a -0.31% decrease in ResMed's stock price; this decline could be attributed to the significant sell-off by institutional investors such as KBC Group NV and insider selling activities within the company.
|
| 2024-06-05 | +0.98 % |
|
| 2024-06-04 | +1.83 % |
- Summary: Parallel Advisors LLC increased its position in ResMed Inc. stock by 15.4%, with other institutions also investing in the company, resulting in ResMed's stock price going up by 1.83%; analysts have given ResMed a "Moderate Buy" rating and an average price target of $202.80.
Reason for ResMed's stock increase: The increase in institutional investment in ResMed, along with positive quarterly earnings results that beat estimates, revenue growth, strong return on equity, and insider buying, contributed to the uptick in the stock price.
- The ResMed Inc. (RMD) stock went up by 1.83% last night as Rathbones Group PLC acquired a new stake in the company, alongside other institutional investors and positive guidance from research firms, such as having a consensus rating of "Moderate Buy" and a consensus target price of $202.80, among other factors like its latest earnings report showing higher-than-expected earnings and revenue growth.
|
| 2024-05-31 | -1.44 % |
|
| 2024-05-30 | +1.64 % |
|
| 2024-05-23 | -3.07 % |
- The article discusses ResMed (RMD) showcasing new research on sleep conditions and the effectiveness of PAP therapy, with studies highlighting the benefits of PAP therapies for patients with sleep disorders, including obstructive sleep apnea. Despite this positive research, the stock went down by -3.07%, potentially due to broader market fluctuations, investor sentiment, or other external factors affecting the stock price.
- Summary: The article discusses ResMed Inc.'s Q3 fiscal year 2024 earnings call, which highlighted strong performance and growth in various aspects of their business. However, despite positive results, ResMed stock experienced a -3.07% drop the previous night.
Reason for Stock Decrease: The decline in ResMed's stock price could be due to various factors such as overall market conditions, investor sentiment, reactions to specific statements made during the earnings call, or external economic influences impacting the healthcare sector.
|
| 2024-05-21 | -0.21 % |
- Summary: The article discusses ResMed (RMD) stock, which has been performing well in 2024 with a 29% increase in share price. The stock had a slight decrease of -0.21% last night, partially attributed to concerns regarding the impact of GLP-1 obesity drugs like Ozempic on ResMed's earnings, as investors feared a potential reduction in the demand for sleep apnoea machines due to the drugs eradicating obesity, which is a common risk factor for sleep apnoea.
Reasons for RMD stock going down: The article mentions that ResMed's stock saw a decline due to a general healthcare sector sell-off and investor concerns about the impact of GLP-1 obesity drugs potentially decreasing the demand for sleep apnoea machines, leading to worries about the company's future earnings.
- The article discusses four ASX shares favored by billion-sized managed funds, including CSL, Aristocrat Leisure Ltd, ResMed Inc, and Goodman Group, with ResMed being the "most loved" stock by fund managers; the reason for ResMed's stock going down may be due to short-term market trends or challenges facing the company.
|
